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Introduction
The recent advances in the management of juvenile
idiopathic arthritis (JIA) have increased considerably the
potential to achieve disease remission or, at least, low
levels of disease activity, and have consequently moved
the therapeutic aims towards the attainment of inactive
disease (ID). Complete disease quiescence is regarded as
the ideal therapeutic target because its achievement
helps preventing further joint damage and disability and
may enhance physical function and quality of life.
Objectives
These issues have led to suggest that a tight control
approach should be adopted in the management of JIA.
We describe our experience with treat-to-target strategy.
Methods
Starting in March 2007, a treat-to-target approach to the
management of all children with JIA first seen in the
senior author’s clinic was implemented, setting achieve-
ment of ID as primary goal and of minimal disease activ-
ity (MDA) or parent-acceptable symptom state (PASS) as
secondary goals. In case primary goal was not reached,
treatment was intensified as deemed necessary. Patient
records were reviewed to evaluate the frequency of
achievement of the therapeutic goals at 6, 12, 18 and 24
months following initial evaluation. ID, MDA and PASS
were defined according to both established criteria and
Juvenile Arthritis Disease Activity Score (JADAS) cutoffs.
The outcome of patients who achieved or did not achieve
ID at last follow-up visit was compared by means of the
Juvenile Arthritis Functionality Scale (JAFS) and the
Pediatric Rheumatology Quality of Life scale (PRQL).
Results
A total of 175 patients (77.7% females) were enrolled.
The most common ILAR subtypes were persistent oli-
goarthritis (53.1%), extended oligoarthritis (14.9%), and
RF-negative polyarthritis (14.3%); 3.4% of patients had
systemic arthritis. The median age at disease onset was
2.8 years. At baseline visit, the median age was 3.5 years
and the median disease duration was 0.2 years. Initial
therapeutic interventions included intra-articular corti-
costeroid injection (84%), methotrexate (28%), systemic
corticosteroids (5.7%), and biologic medications (1.1%).
The frequency of achievement of treatment goals at
study endpoints is shown in the table. At last follow-up
visit, patients who had achieved ID had better functional
ability (p = 0.007) and physical well-being (p = 0.007)
than those who did not. The frequency of clinical remis-
sion on medication was 29.2%. (Table 1)
Conclusion
At 2 years after initial visit, a substantial percentage of
patients had reached the states of ID or MDA or were in
PASS. Patients who achieved ID had better physical func-
tion and well-being than those who did not. These findings
suggest that the implementation of a treat-to-target
approach may help improve patient outcomes.
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50(35.2) 62(43.7) 76(66.1) 43(31.6) 43(31.6) 64(47.1)
12 months
N(%)
48(41) 71(60.7) 77(74.8) 46(41.4) 58(52.3) 66(59.5)
18 months
N(%)
46(47.4) 60(61.9) 69(82.1) 43(46.2) 60(64.5) 67(72)
24 months
N(%)
45(50.6) 5(59.6) 53(70.7) 33(39.3) 40(47.6) 52(61.9)
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